title: Validation of QuickDASH outcome measure in breast cancer survivors for upper extremity disability.
abstract: OBJECTIVE
  To validate the QuickDASH as a patient-reported outcome measure for assessing upper extremity disability in breast cancer survivors.
  
  
  METHODS
  Large cross-sectional survey.
  
  
  METHODS
  Ambulatory care center at a university hospital.
  
  
  METHODS
  Postmenopausal women (N=150) with stage I to III hormone receptor-positive breast cancer currently taking a third-generation aromatase inhibitor.
  
  
  METHODS
  Not applicable.
  
  
  METHODS
  QuickDASH, an 11-item self-administered questionnaire, assesses global arm function over the past 7 days.
  
  
  RESULTS
  Of 150 surveys, 148 (99%) were scorable. The factor analysis demonstrated 1 factor with an eigenvalue of 6.7, which explains 61% of variance. The score was reliable with a Cronbach alpha of .93. The test-retest reliability was .78 over 2 weeks. The mean QuickDASH score ± SD for all patients was 19±19. Those with upper extremity arthralgias reported higher QuickDASH scores than controls without pain (26 vs 12, P=.001). Those with frozen shoulder pain also reported higher QuickDASH scores than controls without pain (37 vs 15, P=.001).
  
  
  CONCLUSIONS
  The QuickDASH instrument is a convenient, reliable, and valid patient-reported outcome measure to assess upper extremity disability in patients with breast cancer.
authors.affiliation: Department of Physical Medicine and Rehabilitation, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA. Electronic address: mously.leblanc@uphs.upenn.edu.
authors.forename: Mously
authors.initials: M
authors.lastname: LeBlanc
authors.affiliation: Department of Physical Medicine and Rehabilitation, University of Pennsylvania Health System, Philadelphia, PA; Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA.
authors.forename: Margaret
authors.initials: M
authors.lastname: Stineman
authors.affiliation: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA.
authors.forename: Angela
authors.initials: A
authors.lastname: DeMichele
authors.affiliation: Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA.
authors.forename: Carrie
authors.initials: C
authors.lastname: Stricker
authors.affiliation: Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Health System, Philadelphia, PA; Abramson Cancer Center, University of Pennsylvania Health System, Philadelphia, PA; Department of Family Medicine and Community Health, University of Pennsylvania Health System, Philadelphia, PA.
authors.forename: Jun J
authors.initials: JJ
authors.lastname: Mao
mesh_terms: D000368:Aged; D047072:Aromatase Inhibitors / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology*; D003430:Cross-Sectional Studies; D004185:Disability Evaluation; D005260:Female; D006785:Hospitals, University; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D026741:Physical Therapy Modalities; D017698:Postmenopause; D017741:Survivors; D034941:Upper Extremity / Q000503:physiopathology*
chemical_list: D047072:Aromatase Inhibitors
keywords: Breast neoplasms; Disability evaluation; Rehabilitation; Upper extremity; Validation studies